ChinaBio Partnering Forum EBD GroupChinaBIO
Share:
Email this page Share this on LinkedIn Share this on Twitter

ChinaBio® Partnering Forum 2014 Press Releases

May 14, 2014Sixth annual ChinaBio® Partnering Forum reports record attendance at Suzhou event ChinaBio® Partnering Forum 2014, China's largest life science partnering event, concluded last week in Suzhou, China with record attendance of 848 delegates from 425 companies, an increase of nearly 100 delegates over 2013. Delegates from 25 countries representing senior leadership in multinational pharmaceutical and large biotech drug development companies met with innovative...  more ►

April 28, 2014ChinaBio® Partnering Forum 2014 Program is uniquely designed for global life science companies seeking cross-border partnerships ChinaBio® Partnering Forum 2014, China's largest life science partnering event, will be held in one week, May 7–8, in Suzhou, China. The 2014 event kicks off with the widely acclaimed "Partnering Bootcamp: How to partner with global pharma," a special half-day global partnering bootcamp designed for entrepreneurs and executives in China to take their life science busines...  more ►

April 3, 2014Involvement of international pharmaceutical companies in ChinaBio® Partnering Forum 2014 echoes compelling China market demand The 2014 edition of ChinaBio® Partnering Forum, China's only life science partnering event, is just weeks away, to be held May 7–8 at the Kempinski Hotel in Suzhou. Pharma companies strongly support the event, as many international companies seek to access the massive healthcare market and partnership opportunities for growth in China. AstraZeneca, Bayer, Bristol-Myers S...  more ►

April 2, 2014Spotlight on Suzhou Business Facts BioBay innovation cluster BioBay, located in the Dushu Lake Science and Education Innovation District in Suzhou, is an innovative science and technology carrier for development of the emerging biological industry, among other initiatives. Currently there are over 400 biotech companies in BioBay. Suzhou Industrial Park The Suzhou Industrial Park (SIP) is the largest in China, a...  more ►

February 5, 2014China's largest life science partnering event returns to Suzhou, ChinaChinaBio® Partnering Forum 2014 to draw pharma and biotech dealmakers
The 2014 edition of ChinaBio® Partnering Forum, China's premier life science partnering event, will be held May 7–8 at the Kempinski Hotel in Suzhou. In 2013, the Forum was attended by more than 750 delegates from 405 companies and 22 countries, making it the largest partnering conference in China. Pharma and biotech companies as well as leading researchers from China's ...  more ►



partnering360:Insight Latest headlines from partnering360:Insight

23 July 2014 Medtrack Unpartnered Products: Partnerships that could be Game Changers As the pharmaceutical landscape continues to consolidate through acquisitions and partnerships, Medtrack Analyst Steven Muntner examines the untapped market of unpartnered products, which represents a potential multi-billion dollar opportunity. more ►

22 July 2014 Promethera expands portfolio with progenitor cell platform Eric Halioua arrives at BioPharm America™ in Boston this September carrying an expanding portfolio of partnering opportunities based on a platform of human liver progenitor cells. more ►

22 July 2014 CoStim Pharma: People plus hot science create stunning combo-combo deal Pathways and platforms are great but true exits come around product portfolios, says Robert Millman, a founder and the chief executive for CoStim Pharmaceuticals, which was snapped up by Novartis just 10 months after the company's first funding round. more ►

21 July 2014 Recent industry analysis on distribution partnering agreements Recent industry analysis from Current Agreements shows a high volume of dealmaking activity in the distribution deal type among the pharma and biotech companies worldwide. more ►

12 May 2014 Market Update: Cancer Immunotherapy Perhaps no other recent topic in oncology has generate as much excitement as the immunotherapies. PD-1s, checkpoint inhibitors, CAR-T, and DC therapies – all have become common fare for those following cancer drug development. more ►



Arrow Up


 
 
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD Group, Inc.
Privacy Policy
Terms of Use
ChinaBio Partnering Forum EBD GroupChinaBIO